The Index
Every company in our coverage — the builders, studios and houses we write about. Each one gathers its articles, jobs and listings in a single place.
15 companies · Genomics
Genomics
A negative-EV ($-60M) clinical-stage AAV play where the market prices the entire pipeline below cash — fully funded into 2H 2028 with two binary Phase 3 wet-AMD readouts (4FRONT-1 1H'27, 4FRONT-2 2H'27) standing between it and either a re-rate or a wipeout; best-in-class intravitreal tolerability is the edge, durability-vs-Eylea-HD/faricimab is the kill switch.
Genomics
The first RNAi company to scale to profitability — Amvuttra's ATTR-CM launch turned a 20-year science project into a >$5B-revenue franchise inflecting at +71% guided; the bet is whether durable TTR leadership + a 40-program pipeline justify ~70x forward earnings before nucresiran fixes the Sanofi royalty drag.